# G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for RAEB-1,REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT

> **NCT04713956** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 242 (estimated)

## Conditions studied

- Myelodysplastic Syndrome
- Allogeneic Hematopoietic Stem Cell Transplantation
- Conditioning

## Interventions

- **DRUG:** Granulocyte Colony-Stimulating Factor(G-CSF)
- **DRUG:** Decitabine (DAC)
- **DRUG:** Busulfan (BU)
- **DRUG:** Cyclophosphamide (CY)
- **DRUG:** Fludarabine (FLU)

## Key facts

- **NCT ID:** NCT04713956
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-15
- **Primary completion:** 2023-07-31
- **Final completion:** 2024-07-31
- **Target enrollment:** 242 (ESTIMATED)
- **Last updated:** 2021-01-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04713956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04713956, "G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for RAEB-1,REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04713956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*